Direct thrombolytic therapy for intraventricular thrombosis in patients with the Jarvik 2000 left ventricular assist device

Journal of Heart and Lung Transplantation

Volumn 24, Issue 2, 2005, Pages 231-233

  Delgado III, Reynolds ^a   Frazier, O H ^a   Myers, Timothy J ^a   Gregoric, Igor D ^a   Robertson, Kimberly ^a   Shah, Nyma A ^a   Kar, Biswajit ^a  

^a TEXAS HEART INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; HEPARIN; WARFARIN;

ADULT; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CASE REPORT; DOSE RESPONSE; FIBRINOLYTIC THERAPY; HEART ASSIST DEVICE; HEART CATHETERIZATION; HEART VENTRICLE THROMBOSIS; HUMAN; MALE; PRIORITY JOURNAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 13444261166     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2003.10.023     Document Type: Article

References (3)

1. Noon G.P., Morley D.L., Irwin S., Abdelsayed S.V., Benkowski R.J., Lynch B.E. Clinical experience with the MicroMed DeBakey ventricular assist device. Ann Thorac Surg. 71:(suppl 3):2001;S133-138
2. Frazier O.H., Myers T.J., Gregoric I.D., et al. Initial clinical experience with the Jarvik 2000 implantable axial-flow left ventricular assist system. Circulation. 105:2002;2855-2860
3. The GUSTO angiographic investigators. The comparative effects of tissue plasminogen activator, streptokinase, or both on coronary patency, ventricular function and survival after myocardial infarction. N Engl J Med. 329:1993;1615-1622